POTASSIUM CLORIDE INJECTIONS
The trading (patented) name of a preparation - KCl 4% FOR INJECTIONS
The international name - Potassium Chloride For Injections
ATC-CODE - A12BA01
Colorless transparent liquid
STRUCTURE AND THE FORM OF RELEASE
1 litre of a solution contains
Potassium chloride ............ 40 g
Other components: water for injection.
100, 200 ml of solution in plastic PVC containers.
Potassium is the major intracellular ion. Reduces the stimulation of myocarditis, being the antagonist of cardiac glycosides in effecting the rhythm of heart, it holds their favourable inotropic effect. Potassium intake exceeds the acetylcholine contents and stimulation of sympathetic system; during administration of potassium stimulation of adrenal glands with the increased allocation of adrenaline is registered. The preparation enhances muscular pressing during muscular dystrophia, myasthenia.
Pharmcokinetics. Absorbed good and quickly, removed through kidneys.
INDICATIONS FOR ADMINISTRATION
- hyperkalemia or non metabolic alkalosis;
- intoxication with foxglove preparations;
- prevention of hyperkalemia in patients with arrhythmic heart or patients who received foxglove preparations;
- electrolyte balance disorder during liver cyrosis, accompanied by ascite during nefropathy, and heavy diarrhoea.
Administered intravenously with controlled rate (20 – 30 drop/min.) up to 2,5 gr in the isotonic solution of sodium chloride 500 ml or in glucose 5 % solution.
Hyperkalemia (6,5 - 8,0 mEq/liter), first symptoms include ECG changes (peaking of Ò-waves, loss of P-waves, depression of S-T Segment and prolongation of the QT interval) . Late manifestations include (9 - 12 mEq/liter): muscle paralysis and cardiovascular collapse from cardiac arrest. Paresthesia (first sign).
Intestines: nausea, vomiting, diarrhea, abdominal spasm/discomfort. Other: pain, thrombosis or phlebitis extending from the site of intravenous injection.
Hyperkalemia, hypochloremia (hypochloremic alkolosis), renal failure, cardiac arrest.
The concomitant administration of potassium salts and potassium-sparing diuretic (e.g. spironolactone, triamterene or amiloride), non-steroid anti-inflammatory means can produce severe hyerkalemia and cardiac arrhythmia.
Should be administred intravenously only with controlled rate because of the higher risk of hyperkalemia, mostly in patients with renal insufficiency. Symptoms include: Paresthesias of extremities, weakness and heaviness of the legs, flaccid paralysis, heart block.
Potassium should be used with caution in patients having acute dehydration or extensive tissue breakdawn caused by severe burns.
Prolonged parenteral therapy requires careful attention to the serum electrolyte concentration levels and the ECG.
During potassium chloride conductivity deficiency it should be used with caution.
STORAGE CONDITIONS AND SHELF LIFE
The preparation must be stored in a dark place protected from light in regular conditions.
Expiry date of the intravenous solution - 2 years.